TNF and inflammatory bowel disease: The adjusted CMIA cut-off value of approximately 1100 AU/mL demonstrated a diagnostic performance sufficient to stratify patients in routine clinical settings, enabling clinicians to identify IBD patients under anti-TNF therapy who are unlikely to have developed neutralizing antibodies and who may therefore benefit from additional protective strategies.